Jiangsu Apon Medical Technology Co., Ltd.

SZSE:300753 Stock Report

Market Cap: CN¥1.8b

Jiangsu Apon Medical Technology Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Zhi Hui Zhang

Chief executive officer

CN¥511.6k

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure2.3yrs

Recent management updates

Recent updates

Jiangsu Apon Medical Technology Co., Ltd.'s (SZSE:300753) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Oct 09
Jiangsu Apon Medical Technology Co., Ltd.'s (SZSE:300753) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Insufficient Growth At Jiangsu Apon Medical Technology Co., Ltd. (SZSE:300753) Hampers Share Price

Jul 02
Insufficient Growth At Jiangsu Apon Medical Technology Co., Ltd. (SZSE:300753) Hampers Share Price

Jiangsu Apon Medical Technology Co., Ltd.'s (SZSE:300753) Share Price Boosted 41% But Its Business Prospects Need A Lift Too

Mar 08
Jiangsu Apon Medical Technology Co., Ltd.'s (SZSE:300753) Share Price Boosted 41% But Its Business Prospects Need A Lift Too

CEO

Zhi Hui Zhang (53 yo)

no data

Tenure

CN¥511,600

Compensation

Mr. Zhi Hui Zhang serves as General Manager, Managing Director and Director of Jiangsu Apon Medical Technology Co., Ltd.


Board Members

NamePositionTenureCompensationOwnership
Zhi Hui Zhang
GM, MD & Directorno dataCN¥511.60kno data
Ningyu Wang
Chairmanno dataCN¥541.10k34.22%
CN¥ 625.4m
Jifeng Guan
Directorno datano data0.47%
CN¥ 8.6m
Lizhong Wang
Non-Independent Director2.3yrsno datano data
Xiangyong Kong
Independent Director2.3yrsCN¥120.00kno data
Liyang Hou
Independent Director2.3yrsCN¥120.00kno data
Hongxun Tao
Independent Director2.3yrsCN¥120.00kno data
Hao Tang
Supervisor2.3yrsno datano data
Xinchuang Yuan
Supervisory Board Chairman2.3yrsno datano data

2.3yrs

Average Tenure

53yo

Average Age

Experienced Board: 300753's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.